Trial Profile
PHASE II STUDY OF NEOADJUVANT NIVOLUMAB IN PATIENTS WITH GLIOBLASTOMA MULTIFORME
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Apr 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Nivolumab (Primary)
- Indications Glioblastoma
- Focus Pharmacodynamics
- 10 Apr 2017 Status changed from recruiting to completed.
- 26 Aug 2015 New trial record